Please ensure Javascript is enabled for purposes of website accessibility

CRISPR Therapeutics and Vertex Pharmaceuticals Deliever New CTX001 Data

By Cory Renauer – Jun 12, 2020 at 2:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The partners reported encouraging results from the first four patients treated with the CRISPR-based gene-editing therapy.

Gene therapy took another public step forward during a virtual presentation at a scientific conference on Friday. CRISPR Therapeutics (CRSP -3.44%) and Vertex Pharmaceuticals (VRTX 2.73%) presented updated results from studies with CTX001, the first CRISPR-based gene-editing therapy to reach human-stage testing.

Meeting goals 

In the Climb-111 trial treating transfusion-dependent beta-thalassemia (TDT), CTX001 drastically reduced patients' dependence on frequent blood transfusions. In the years leading up to the trial, Patient 1 required 34 units of red blood cells annually and Patient 2 needed transfusions at a rate of 61 units per year. At 15 months following a single infusion of CTX001, patient 1 still hasn't required a transfusion. At the five-month mark, patient 2 hasn't required a transfusion either.

Microscope close up

Image source: Getty Images.

In the Climb-121 trial treating severe sickle cell disease, an infusion of CTX001 appeared successful for the first two patients treated. Treatment with CTX001 should lead to the body producing healthy fetal hemoglobin to replace the faulty hemoglobin at the source of their blood disorders.

Patience will be required

It could be a long time before we know if Vertex and CRISPR have a new marketable treatment option for sickle cell disease. The Climb-121 trial will look for fetal hemoglobin levels of 20% or higher sustained for at least three months. The observation window doesn't begin until six months after treatment and it lasts for a year and a half.

Climb-121 and Climb-111 are intended to enroll around 45 patients, but CRISPR and Vertex had to pause conditioning and dosing newly enrolled patients entering both studies due to the COVID-19 pandemic. The companies have resumed dosing at some locations and they expect to report more data in the second half of the year.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$63.10 (-3.44%) $-2.25
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$297.43 (2.73%) $7.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.